The company plans to recruit one million patients from Mexico over three years and then expand to Columbia, Argentina, and Brazil.
The single-cell approach enabled them to identify gene expression in rare cell types, highlighting a previously unrecognized role for these cells in diabetes.
University of Cambridge researchers found that people who learned their genetic risk of developing diabetes did not have increased motivation to make lifestyle changes.
The effort aims to identify a suite of markers that could aid in management of type II diabetes and related conditions like retinopathy and kidney damage.
The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.
The results of this meta-analysis by University of Cambridge-led team could have implications for LDL-C-lowering therapies.
Researchers saw both short- and long-term changes in metabolite profiles in blood plasma from individuals who'd undergone Roux-en-Y gastric bypass surgery.
Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.
The core technology uses proximity-ligated amplification and the firm will build it into tests for type I diabetes as well as highly multiplexed assays.
In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.